Abstract
Negative results in therapeutic trials in Alzheimer's disease (AD) usually account for the nonefficacy of the presently tested drugs. However, methodological flaws in the design of these studies, related to the commonly used nosographic approach, can also be implicated in the lack of demonstration of beneficial results. With regard to the heterogeneity of clinical manifestations of AD, the interest of the dimensional, transnosographic approach to cognitive deficits and behavioral disturbances in dementia is suggested for these trials. Both approaches can also be combined, according to the presumed biochemical action of the tested drug in the preclinical studies and the aim of the trial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
